<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04291053</url>
  </required_header>
  <id_info>
    <org_study_id>TJ-IRB20200205</org_study_id>
    <nct_id>NCT04291053</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19</brief_title>
  <official_title>The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in
      Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000
      people were infected and over 2000 people died all over the world.There is no specific drug
      treatment for this disease. This study is planned to observe the efficacy and safety of
      Huaier granule in the adjuvant treatment COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>up to 28 days</time_frame>
    <description>All cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical status assessed according to the official guideline</measure>
    <time_frame>up to 28 days</time_frame>
    <description>1.mild type：no No symptoms, Imaging examination showed no signs of pneumonia; 2,moderate type: with fever or respiratory symptoms,Imaging examination showed signs of pneumonia, SpO2&gt;93% without oxygen inhalation ; severe type:Match any of the following：a. R≥30bpm；b.Pulse Oxygen Saturation(SpO2)≤93% without oxygen inhalation，c. PaO2/FiO2(fraction of inspired oxygen )≤300mmHg ；4. Critically type：match any of the follow: a. need mechanical ventilation; b. shock; c. (multiple organ dysfunction syndrome) MODS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences in oxygen intake methods</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Pulse Oxygen Saturation(SpO2)&gt;93%，1. No need for supplemental oxygenation; 2. nasal catheter oxygen inhalation（oxygen concentration%,The oxygen flow rate：L/min）；3. Mask oxygen inhalation（oxygen concentration%,The oxygen flow rate：L/min）；4. Noninvasive ventilator oxygen supply（Ventilation mode,oxygen concentration%,The oxygen flow rate：L/min,）；5. Invasive ventilator oxygen supply（Ventilation mode,oxygen concentration%,The oxygen flow rate：L/min,）.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of supplemental oxygenation</measure>
    <time_frame>up to 28 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of mechanical ventilation</measure>
    <time_frame>up to 28 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean PaO2/FiO2</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay (days)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay (days)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>up to 3 months after discharge</time_frame>
    <description>forced expiratory volume at one second ,maximum voluntary ventilation at 1month，2month，3month after discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy+Huaier granule Huaier granule 20g, po, tid for 2 weeks( or until discharge)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huaier Granule</intervention_name>
    <description>standard treatment + Huaier Granule 20g po tid for 2weeks</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 18 and 75 years, extremes included, male or female

          2. Patients diagnosed with mild or common type COVID-19, according to the official
             guideline &quot;Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection
             (Trial Version 6)&quot;

          3. patients can generally tolerable for treatment recommended by the official guideline
             &quot;Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial
             Version 6)&quot;

          4. Patients have not been accompanied by serious physical diseases of heart, lung, brain,
             etc.,Eastern Cooperative Oncology Group score standard:0-1

          5. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Female subjects who are pregnant or breastfeeding.

          2. patients who are allergic to this medicine

          3. patients meet the contraindications of Huaier granule

          4. Patients with diabetes

          5. Patients have any condition that in the judgement of the Investigators would make the
             subject inappropriate for entry into this study.

          6. patients can't take drugs orally
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Chen</last_name>
    <phone>+8613517260864</phone>
    <email>chenlin_tj@126.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Chen Xiaoping</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Huaier granule</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

